Lung Infection: Clinical Trials

5 trials for Lung Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 unknown. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 3, Recruiting 1, Unknown 1
Phase 22Completed 1, Unknown 1

Follow Lung Infection: new trials by email Literature Review of Lung Infection trials Research Report on Lung Infection

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
Opaganib, Placebo - COVID-19, Lung Infection
Phase 2 / Phase 3CompletedRedHill Biopharma Limited4752020-08-212025-07-31
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
AR-301, Placebo - Lung Infection, Pneumonia, Ventilator-Associated
Phase 3CompletedAridis Pharmaceuticals, Inc.1742019-05-032023-07-06
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
Clarithromycin 1000 MG, Azithromycin 250 mg, Rifampicin - Lung Infection, MAC Lung Disease
Phase 3RecruitingCentre Hospitalier Universitaire, Amiens4242018-02-052025-11-19
Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage
rhubarb, Placebo - Lung Infection, Cerebral Hemorrhage
Phase 2 / Phase 3UnknownFudan University1002009-01-012010-05-28
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa
AZLI 75 mg three times daily (TID), Placebo three times daily (TID) - Cystic Fibrosis, Lung Infection
Phase 3CompletedGilead Sciences1602008-05-012010-12-20

Narrower conditions

Pneumonia (2)  ·  Bacterial Infections (1)  ·  COVID-19 (1)  ·  Cerebral Hemorrhage (1)  ·  Cystic Fibrosis (1)  ·  Infections (1)  ·  Pneumonia, Ventilator-Associated (1)  ·  Pseudomonas Infections (1)  ·  Staphylococcal Infections (1)

Broader conditions

Lung Diseases (4)  ·  Respiratory Tract Diseases (4)  ·  Infections (3)  ·  Respiratory Tract Infections (3)  ·  Bacterial Infections and Mycoses (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Bacterial Infections (1)  ·  Brain Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)

Interventions

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (1)  ·  Azithromycin (1)  ·  Clarithromycin (1)  ·  Ethambutol (1)  ·  Rifampin (1)  ·  rhubarb peony decoction (1)

Sponsors

Aridis Pharmaceuticals, Inc. (1)  ·  Centre Hospitalier Universitaire, Amiens (1)  ·  Fudan University (1)  ·  Gilead Sciences (1)  ·  RedHill Biopharma Limited (1)

Countries

Brazil (2)  ·  China (2)  ·  France (2)  ·  Israel (2)  ·  Mexico (2)  ·  Russia (2)  ·  United States (2)  ·  Australia (1)  ·  Belarus (1)  ·  Belgium (1)  ·  Canada (1)  ·  Colombia (1)  ·  Estonia (1)  ·  Georgia (1)  ·  Italy (1)

Top investigators

Claire Wainwright, MD (1)  ·  Hasan S Jafri, MD, FAAP (1)  ·  Mark L Levitt, MD (1)  ·  Ron Gibson, MD (1)

Results publications

PMID 21441078